Children aged <2 years are at increased risk for influenzarelated hospitalizations (1-3). Beginning in 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged that, when feasible, all children aged 6-23 months, as well as household contacts and out-of-home caregivers for children aged <2 years, receive influenza vaccinations each influenza season (1). Beginning with the 2004-05 influenza season, ACIP strengthened the encouragement to a recommendation (4). Other children recommended to receive influenza vaccine continue to include those aged 6 months-18 years with certain high-risk medical conditions and those aged 6 months-18 years who are household contacts of persons at high risk for influenza complications (4). This report on childhood influenza-vaccination coverage for the 2002-03 influenza season provides a baseline for the continuing assessment of coverage among children aged 6-23 months. The findings demonstrate that, during the first year of the ACIP encouragement to vaccinate children aged 6-23 months against influenza, vaccination coverage was low, with substantial variability among states and urban areas.
Childhood Influenza-Vaccination Coverage -United States, 2002-03 Influenza Season
Children aged <2 years are at increased risk for influenzarelated hospitalizations (1) (2) (3) . Beginning in 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged that, when feasible, all children aged 6-23 months, as well as household contacts and out-of-home caregivers for children aged <2 years, receive influenza vaccinations each influenza season (1) . Beginning with the 2004-05 influenza season, ACIP strengthened the encouragement to a recommendation (4) . Other children recommended to receive influenza vaccine continue to include those aged 6 months-18 years with certain high-risk medical conditions and those aged 6 months-18 years who are household contacts of persons at high risk for influenza complications (4) . This report on childhood influenza-vaccination coverage for the 2002-03 influenza season provides a baseline for the continuing assessment of coverage among children aged 6-23 months. The findings demonstrate that, during the first year of the ACIP encouragement to vaccinate children aged 6-23 months against influenza, vaccination coverage was low, with substantial variability among states and urban areas.
This report is based on data from the 2003 National Immunization Survey (NIS), an ongoing survey that provides estimates of vaccination coverage among noninstitutionalized children aged 19-35 months. Children included in the 2003 NIS were born during January 2000-July 2002. The survey is conducted in all 50 states and 28 selected urban areas (5) . In 2003, entire influenza-vaccination histories were obtained for all children.
Two measures of childhood influenza-vaccination coverage are reported: 1) receipt of one or more influenza vaccinations during September-December 2002 and 2) full vaccination (based on ACIP recommendations for 2 doses of influenza vaccine for previously unvaccinated children aged <9 years and 1 dose for previously vaccinated children aged <9 years) (4) . Children were considered fully vaccinated if they had 1) received no doses of influenza vaccine before September 1, 2002, but then received 2 doses from September 1 through either the date of interview or January 31, 2003, or 2) received >1 dose of influenza vaccine before September 1 and then received >1 dose during September-December 2002. Because children aged <6 months are not eligible for vaccination and because the encouragement (and now the recommendation) calls for vaccination of children aged 6-23 months, analyses for both measures included only those children who were aged 6-23 months during the entire span of SeptemberDecember 2002.
In the 2003 NIS, the overall response rate for eligible households was 62.7%, and 13,831 children (unweighted) met the age criteria for this assessment. Of these, 7.4% (+0.7) received one or more influenza vaccinations, and 4.4% (+0.5) were fully vaccinated (Table) . Substantial variability in influenza coverage was observed among states and selected urban areas. Percentages of children receiving one or more influenza vaccinations ranged from 2.2% (+2.1) in El Paso County, Texas, to 26.6% (+8.0) in Rhode Island.
Editorial Note: The findings in this report indicate that, during the first season in which ACIP encouraged childhood influenza vaccination, coverage was low and varied substantially among states. These first national estimates of childhood influenza-vaccination coverage provide a baseline for assessing implementation of the pediatric influenza-vaccination program recommended by ACIP.
Coverage estimates for other routinely recommended childhood vaccines also vary across states and urban areas (6) . Further study is needed to determine the reason for such variation and to identify useful strategies for increasing annual influenza vaccination among all groups of children (and adults) for whom the vaccine is now recommended (4) .
During the 2002-03 influenza season, influenza vaccination of healthy children aged 6-23 months was not yet covered by the Vaccines for Children Program (VFC) and also might not have been covered by the majority of private health plans. The ACIP encouragement rather than full recommendation and the lack of VFC coverage both likely contributed to the low coverage observed during the 2002-03 influenza season. However, beginning with the 2003-04 influenza season, ACIP voted to include in the VFC program annual influenza vaccination for all children aged 6-23 months and for household contacts of children aged <2 years. This expansion of VFC coverage for influenza vaccine enables providers to administer free influenza vaccine to the most vulnerable groups of children (i.e., Medicaid enrollees, uninsured children, American Indian/Alaska Native children, and certain children whose health insurance does not cover the cost of vaccination). More doses of influenza vaccine were produced and available than eventually were used for the 2002-03 influenza season, so problems of inadequate vaccine supply were unlikely to have contributed to the low vaccination coverage during that season.
The vaccination rates described in this report might, in part, reflect implementation of the long-standing recommendation to administer influenza vaccine to children aged >6 months who have a high-risk condition or who live with a child or adult with a high-risk condition. However, this possibility could not be verified because NIS does not collect information on high-risk medical conditions or household contacts with high-risk conditions. In the United States, an estimated 5.5% of children aged 6-23 months have a high-risk condition for which influenza vaccination is recommended (7) . Although national vaccination-coverage data are not available for groups at high risk, studies of specific populations have reported influenza coverage among children at high risk, ranging from 7% to 79% (4, 8, 9) . In the 2004 NIS, information on risk status of children aged 19-35 months at the time of interview and of their household contacts is being collected for a subsample of households. Additional mechanisms are needed to assess coverage among children aged >35 months, including those who have one or more high-risk medical conditions or who live with a person at high risk (e.g., a child aged <2 years).
Two decisions made during analysis might have influenced, in opposite directions, the vaccination-coverage estimates. First, analysis was limited to those vaccinations administered during September-December for the 1+ FLU measure and during September 1, 2002-January 31, 2003 (or date of interview if the interview occurred before January 31) for the fully vaccinated measure, although some vaccines might have been administered after these months and would not have been counted. This approach possibly reduced both measures of influenza-vaccination coverage reported here, particularly the estimate of fully vaccinated children, because difficulty in scheduling and returning for the second dose of influenza vaccine might delay receipt of the second dose until later in the influenza season. Second, measurement of vaccination coverage was restricted to children aged 6-23 months during the entire influenza-vaccination period of September-December. Children in this age group were eligible for vaccination under the ACIP encouragement for the entire period of assessment, so their caregivers and providers each had an equal amount of time to ensure vaccination. Therefore, this sample of children likely has higher vaccination coverage than children who were aged 6-23 months during only a portion of the 4-month vaccination interval, thereby potentially inflating the coverage estimate.
The findings in this report are subject to at least three limitations. First, NIS is a telephone survey; although statistical adjustments compensate for expected differences in coverage in households without telephones, coverage bias might remain. Second, NIS relies on provider-verified vaccination histories; incomplete records and reporting might result in underestimates of coverage. Finally, because of sampling uncertainty and wide confidence intervals for many state and urban-area estimates from NIS, these estimates should be interpreted with caution.
Influenza-vaccination coverage among children aged 6-23 months was low during the first year of the ACIP encouragement. For the 2004-05 influenza season, an ACIP recommendation replaces the encouragement that was in place previously (10) ; this change is expected to result in increased vaccination coverage. However, substantial work is needed to fully implement this new recommendation for children aged 6-23 months and household contacts of children aged <2 years and to reduce the number of preventable influenza-related hospitalizations among young children (2). Alcohol-Related Disease Impact (ARDI)* software was used to estimate the number of AADs and YPLLs. ARDI estimates AADs by multiplying the number of deaths from a particular alcohol-related condition by its alcohol-attributable fraction (AAF). Certain conditions (e.g., alcoholic cirrhosis of the liver) are, by definition, 100% alcohol attributable. For the majority of the chronic conditions profiled in ARDI, the system calculates AAFs by using relative risk estimates from metaanalyses (2, 3) and prevalence data on alcohol use from the Behavioral Risk Factor Surveillance System. For some conditions, especially those with an acute onset (e.g., injuries), ARDI includes direct estimates of AAFs. Direct estimates of AAFs are based on studies assessing the proportion of deaths from a particular condition that occurred at or above a specified blood alcohol concentration (BAC) (4, 5 (Table) . Of the 75,766 deaths, 34,833 (46%) resulted from chronic conditions, and 40,933 (54%) resulted from acute conditions. Overall, 54,847 (72%) of all AADs involved males, and 4,554 (6%) involved persons aged <21 years. Of the deaths among males, 41,202 (75%) involved men aged >35 years; of those deaths, 41,202 (58%) were attributed to chronic conditions. For males and females combined, the leading chronic cause of AADs was alcoholic liver disease (12,201), and the leading acute cause of AADs was injury from motor-vehicle crashes (13,674). In addition, in 2001, an estimated 11 lives were saved because of the potential benefits of excessive alcohol use, all of which were attributable to a reduced risk for death from cholelithiasis (i.e., gall bladder disease).
Of the estimated 2,279,322 YPLLs, 788,005 (35%) resulted from chronic conditions, and 1,491,317 (65%) resulted from acute conditions (Table) . Overall, 1,679,414 (74%) of the total YPLLs were among males, and 271,392 (12%) involved persons aged <21 years. Of all YPLLs among males, 973,214 (58%) involved men aged >35 years, of which 53% were attributed to chronic conditions. Deaths from alcoholic liver disease resulted in 316,321 YPLLs, and deaths from motorvehicle-traffic crashes resulted in 579,501 YPLLs.
Editorial Note: In 2001, excessive alcohol use was responsible for approximately 75,000 preventable deaths and 2.3 million YPLLs in the United States. The majority of these deaths involved males (72%), and the majority of the deaths among males involved those aged >35 years (75%). Approximately half of the total deaths and two thirds of the total YPLLs resulted from acute conditions. Moreover, the BAC level used in this analysis for defining an alcohol-attributable injury death (>0.10 g/dL) is higher than the BAC level used by the National Institute for Alcohol Abuse and Alcoholism (8) to define binge drinking (>0.08 g/dL); as a result, all of the injury deaths were attributable to binge alcohol use (i.e., >5 drinks per occasion for men: >4 drinks per occasion for women).
The findings described in this report are similar to recent estimates of AADs attributable to excessive drinking in the United States (1). In contrast, earlier estimates of alcoholrelated deaths (9) were higher than the estimates in this analysis and other recent estimates (1) because they were calculated by using a different methodology and were based on mortality from all levels of alcohol consumption, not just excessive drinking.
The 2.3 million YPLLs for excessive drinking is approximately half of the total YPLLs that were caused by smoking in 1999, the most recent year for which this estimate is available (10), even though mortality attributable to tobacco use is nearly six times higher than that attributable to excessive drinking. This difference exists because many AADs, particularly those caused by injuries, primarily affect youth and young adults, and deaths attributable to tobacco use are uncommon in this population.
The findings in this report are subject to at least six limitations. First, data on alcohol use, which are used to calculate indirect estimates of AAFs, are based on self-reports and might underestimate the true prevalence of excessive alcohol use because of underreporting of alcohol use by survey respondents and sampling noncoverage. Second, the risk estimates used in ARDI were calculated by using average daily alcohol consumption levels that begin at levels greater than those typically used to define excessive drinking in the United States. Third, deaths among former drinkers, who might have discontinued their drinking because of alcohol-related health problems, are not included in the calculation of AAFs, even though some of these deaths might have been alcohol attributable. Fourth, ARDI does not include estimates of AADs for several conditions (e.g., tuberculosis, pneumonia, and hepatitis C) for which alcohol is believed to be an important risk factor but for which suitable pooled risk estimates were not available. Fifth, ARDI exclusively uses the underlying cause of death from vital statistics to identify alcohol-related conditions and does not consider contributing causes of death that This analysis illustrates the magnitude of the health consequences of excessive alcohol use in the United States. In addition to estimating the national health effects of alcohol use, ARDI software also can produce state estimates of AADs and YPLLs. Such state-specific analyses are needed because the prevalence of excessive alcohol use, particularly binge drinking, is known to vary substantially by location. State-specific results also can focus discussions of effective public health strategies (e.g., increasing alcohol excise taxes and screening for alcohol misuse in clinical settings) to prevent excessive alcohol use and its adverse health and social consequences.
Progress Toward Global Eradication of Dracunculiasis, 2002-2003
In 1986, when the World Health Assembly adopted a resolution calling for the eradication of dracunculiasis (i.e., Guinea worm disease), an estimated 3.5 million cases occurred in 20 countries, and 120 million persons were at risk for the disease (1). This report describes the status of the global dracunculiasis eradication program (DEP)* as of the end of 2003 (2,3). The findings indicate substantial overall progress towards eradication in 2003 compared with 2002, a major reduction in cases in Sudan, and an increase in cases in Ghana. Further progress will require 1) increased surveillance in all areas in which dracunculiasis is endemic or was previously endemic, 2) access to areas that lack security, and 3) concentrated efforts in Sudan once peace is achieved.
By the end of 2003, annual incidence of dracunculiasis had been reduced >99% from that estimated in 1986, and eight countries in which the disease was previously endemic (Cameroon, Central African Republic, Chad, India, Kenya, Pakistan, Senegal, and Yemen) were free of the disease. Of the remaining 12 countries in which dracunculiasis remains endemic, five reported <100 cases each (Benin, Cote d'Ivoire, Ethiopia, Mauritania, and Uganda) ( (Table) . However, the percentage of cases that were reportedly contained in 2003 remained <75% for nine of the 12 countries. A case of dracunculiasis is classified as contained if three conditions are met: 1) the infected person is detected within 24 hours of the emergence of the Guinea worm through the skin, 2) actions (e.g., occlusive bandages, counseling, and care of the patient until the worm is extracted) are taken to prevent the person from contaminating sources of drinking water, and 3) the previous two conditions are confirmed by a health-care provider within 7 days of the occurrence.
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Endemic ( 100 cases) > Endemic (<100 cases) Editorial Note: Dracunculiasis is a parasitic infection caused by Dracunculus medinensis. Persons become infected by drinking water from ponds contaminated by copepods (water fleas) that contain immature forms of the parasite. One year later, adult worms approximately 1 meter (40 inches) in length emerge through skin lesions, usually on the lower limbs, which frequently develop severe secondary bacterial infections. No effective treatment or vaccine for the disease exists, and infected persons do not become immune to future infections by the parasite. However, dracunculiasis can be prevented by 1) filtering drinking water through a finely woven cloth, 2) treating contaminated water with the larvicide ABATE ® (temephos), 3) educating persons to avoid entering water sources when Guinea worms are emerging from their bodies, and 4) providing clean water from bore-hole or hand-dug wells (5).
The 12 remaining countries where dracunculiasis is endemic made substantial progress toward eradication in 2003, which reflects intensification of interventions in most areas during 2002. Further improvements in public awareness are expected as a result of targeted mass media campaigns in the three countries with the most cases (Ghana, Nigeria, and Sudan).
In September 2003, a joint program review was held at The Carter Center (Atlanta, Georgia) for the three countries. The delegations included senior ministerial representatives and technical leaders of the eradication programs. All 12 countries developed specific programmatic objectives for 2004; improving interventions remains a key objective. Major obstacles to rapid completion of the campaign include 1) ongoing lack of security in areas of western Africa where dracunculiasis is endemic (e.g., Cote d'Ivoire) and 2) limited funding to meet the challenges of eradicating dracunculiasis in postwar Sudan. All countries should implement daily surveillance in communities where dracunculiasis is known to be endemic to ensure detection and containment as soon as any worm begins to emerge. Moreover, all countries in which dracunculiasis is endemic should implement improved surveillance in large areas in which the disease was previously endemic. 
Tuberculosis Transmission in a Renal Dialysis CenterNevada, 2003
Among persons with chronic renal failure, infection with Mycobacterium tuberculosis is more likely to progress to tuberculosis (TB) (1, 2) . Chronic renal failure is an immunocompromising condition associated with cutaneous anergy, which can result in a false-negative tuberculin skin test (TST) result (3) (4) (5) . In 2003, a health-care worker (HCW) (i.e., a hemodialysis technician) in an outpatient renal dialysis center in Nevada became ill with pulmonary TB, exposing more than 400 patients and other employees. The HCW had a previous positive TST result but never received treatment for TB infection. This report summarizes the results of a contact investigation, which suggested that the HCW had transmitted M. tuberculosis to 29 patients and 13 employees. The findings underscore the need for TB screening and treatment of TB infection for all HCWs and patients at high risk.
Before diagnosis in August 2003, the HCW had experienced 6 weeks of cough, fatigue, and a 14-pound weight loss. Microscopic examination of sputum was 4+ positive for acidfast bacilli (AFB), indicating infectiousness, and sputum culture yielded M. tuberculosis susceptible to all first-line anti-TB medications. The HCW was considered infectious for 3 months before TB diagnosis. During the 3-month period, employees and patients in the dialysis center were considered contacts and evaluated. Employee work schedules and patient dialysis schedules were reviewed to quantify the cumulative hours each person had been exposed to the HCW. In September 2003, initial screening of exposed persons included review of medical history, TB symptoms, and previous TST results. Persons without a previous positive TST result received a TST. All dialysis patients were referred for chest radiographs. Persons with TB symptoms or an abnormal chest radiograph submitted sputum for AFB testing and culture. Persons with a negative TST result (<5 mm induration) during initial testing were retested 12 weeks later. TB disease was defined as clinical signs or symptoms of TB with bacteriologic or radiographic confirmation. Latent TB infection (LTBI) was defined as a positive TST result (>5 mm induration) and exclusion of TB disease by chest radiograph and sputum culture. Patients with a positive TST result who either had a previously documented negative TST result within the preceding 12 months or reported not having a previous positive TST were assumed to be recently infected by the HCW.
As of August 2004, a total of 481 contacts had been identified; 48 (10%) were patients from other jurisdictions who had been referred for evaluation by TB-control programs in their jurisdictions. Of the remaining 433 contacts, 95 (22%) were employees, and 291 (67%) were patients of the dialysis center; an additional 47 (11%) were other contacts*. Of the 433 contacts, 333 (77%) were evaluated (Table) ; 36 (11%) had a previous positive TST result. The remaining 297 contacts received a TST; 48 (16%) had a positive TST result. A total of 41 (12%) of the 333 evaluated contacts reported TB symptoms, but TB disease was excluded by chest radiograph and sputum culture.
The dialysis center employees were assumed to be immunocompetent and used as a surrogate group of contacts to evaluate for evidence of TB transmission. Of the 95 employ- * Other includes relatives of the health-care worker (HCW) with TB (n = two), persons who accompanied patients to the dialysis center (n = 38), and persons with unidentified relationships to the HCW (n = seven). † Persons who underwent review of medical history, TB symptoms, and previous TST results. § Persons evaluated who reported or had a previously documented positive TST result. ¶ Persons who received a TST during this contact investigation. ** Persons with a TST result of >5 mm induration. † † Persons who received a TST immediately after TB was diagnosed in the HCW. § § TST was repeated 12 weeks later on all persons with a negative TST result (<5 mm induration) during the initial screening. ¶ ¶ Documented induration increase of >10 mm compared with a routine TST obtained during the 2-year period before the exposure among persons with a positive TST result.
* Relatives of the HCW, persons who accompanied patients to the dialysis center, and persons with unidentified relationships to the HCW.
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ees identified as contacts, 80 (84%) were evaluated; of these, 12 (15%) had a previously documented positive TST result. The remaining 68 employees received a TST; 13 (19%) had a positive TST result. Employees with positive TST results had chest radiographs that were normal. The 13 employees with a positive TST result were similar to the 55 employees with a negative TST result (i.e., by hours of exposure to the HCW, national origin, race/ethnicity, and age). Six (46%) of the 13 employees with a positive TST result had documented TST conversion (i.e., induration increase of >10 mm compared with a routine TST obtained during the 2-year period before exposure); four worked on the same shift as the HCW.
No routine TB screening program had been conducted for patients at the dialysis center. One patient had a documented negative TST result before the exposure; 16 patients reported a previous positive TST result. Of the 291 patients identified as contacts, 212 (73%) were evaluated; 196 (92%) received a TST. A total of 76 (26%) had chest radiographs; five (7%) had abnormal radiographs, and TB disease was excluded subsequently by sputum culture. A total of 29 (15%) patients had a positive TST result. Patients with a positive TST result were older (median age: 65 years; range: 44-88 years) than those with a negative TST result (median age: 60 years; range: 11-95 years) (p = 0.01, Wilcoxon rank-sum). The median time of exposure to the HCW was the same (16 hours) for patients with positive and negative TST results. Of the 196 patients, 72 (37%) received direct care from the HCW; of these, nine (13%) had a positive TST result. Among the 72 patients, the median time of exposure was not different for those with a positive TST result compared with those with a negative TST result.
Employees with a positive TST result and exposed patients were offered a twice-weekly 9-month regimen of isoniazid. As of September 10, six employees and six patients had completed treatment for LTBI, and two patients had died of unrelated causes while receiving treatment. Two patients are continuing LTBI treatment. No secondary cases have been identified. one patient had a previously documented TST result for comparison; therefore, all 29 patients with a positive TST result were considered recently infected. Because exposure duration did not differ between the employees with positive TST results and those with negative TST results, no minimum level of exposure was associated with risk for infection with M. tuberculosis.
The findings in this report are subject to at least one limitation. The majority of persons with chronic renal failure have impaired delayed-type hypersensitivity, which might result in false-negative TST results (3) (4) (5) . The positive TST results from this investigation likely underestimated the true prevalence of LTBI among these patients.
CDC recommends that after a known exposure to infectious TB disease, immunocompromised persons should receive treatment for presumptive LTBI, regardless of TST result (2) . LTBI treatment was offered to all patients exposed to the HCW, even if their TST remained negative after repeat screening. However, convincing these high-risk contacts of the benefits of treating LTBI often was unsuccessful even after repeat counseling. Therefore, this investigation fell short of the national health objective for 2010 that 85% of TB contacts and other persons at high risk complete a course of treatment for LTBI (6) . Because recently infected contacts are at high risk for having TB disease, the local health department is training the dialysis center employees to detect signs and symptoms of TB disease and ensure that anyone with TB symptoms is identified and treated promptly. If dialysis patients have TB disease diagnosed, maintenance dialysis in airborne isolation is required until they have completed enough anti-TB therapy to demonstrate clinical improvement and have negative M. tuberculosis sputum cultures.
TB infection has a higher risk for progression to TB disease among renal dialysis patients because of their older age and immunocompromised status associated with chronic renal failure and other illnesses (7) . Studies in New Jersey and California have documented TB disease rates six to 11 times greater among hemodialysis patients than among the overall state populations (8, 9) . Because these patients spend more time in health-care settings, when M. tuberculosis infection progresses to TB disease, they can expose other persons who also are at greater risk for disease. Therefore, despite the limitations of TST in this population, early detection and treatment of LTBI is imperative (2) . All dialysis patients should be tested at least once for a baseline TST result and rescreened if TB exposure is detected (2, 10 Figure) . Of these, 507 (32%) cases were reported from California, 355 (22%) from Arizona, and 225 (14%) from Colorado. A total of 897 (58%) of the 1,541 cases for which all data were available occurred in males; the median age of patients was 51 years (range: 1 month-99 years). Illness onset ranged from April 23 to September 14; a total of 48 cases were fatal.
A total of 143 presumptive West Nile viremic blood donors (PVDs) have been reported to ArboNET in 2004. Of these, 51 (36%) were reported from California; 37 (26%) from Arizona; 15 from Texas; 12 from New Mexico; five from Colorado; four from Georgia; three each from Florida, Oklahoma, and South Dakota; two each from Missouri and Wisconsin; and one each from Iowa, Louisiana, Minnesota, Nebraska, North Dakota, and Pennsylvania. Of the 143 PVDs, three persons aged 35, 69, and 77 years subsequently had neuroinvasive illness, and 32 persons (median age: 55 years; range: 17-73 years) subsequently had West Nile fever. Additional information about national WNV activity is available from CDC at http://www.cdc.gov/ncidod/dvbid/ westnile/index.htm and at http://westnilemaps.usgs.gov.
Outbreak of Cyclosporiasis Associated with Snow PeasPennsylvania, 2004
On September 17, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr).
During June-July 2004, public health officials in Pennsylvania were notified of cases of the parasitic disease cyclosporiasis (1,2) among persons associated with a residential facility (e.g., residents, staff, and volunteers). CDC confirmed the diagnosis of Cyclospora cayetanensis infection (1) by examining stool specimens from multiple patients. By early July, local public health officials had been notified of approximately 50 poten- tial cases of cyclosporiasis associated with the facility; onsets of illness were from early June through early July. This report describes the findings of the epidemiologic and traceback investigations, which determined the cases were linked to consumption of raw Guatemalan snow peas at five special events, for which food was prepared by the facility staff, from late May through late June (Table) . This is the first documented outbreak of cyclosporiasis linked to snow peas. The Food and Drug Administration (FDA) and CDC are working with Guatemalan officials to determine the sources of the snow peas and possible modes of contamination.
A case of cyclosporiasis was defined as onset of illness 1-14 days after consumption of food or beverages served at one or more of the five special events. Persons with laboratoryconfirmed cases had infection confirmed by CDC by examining stool specimens for Cyclospora (1) , and at least one gastrointestinal (GI) symptom (i.e., diarrhea [loose or watery stool], nausea, vomiting, abdominal cramps, loss of appetite, or unintentional weight loss) or constitutional symptom (i.e., fever, chills, muscle aches, joint aches, generalized body aches, headache, or fatigue). Persons with probable (clinically defined) cases of infection either had 1) three or more loose or watery stools during a 24-hour period and at least one other symptom or 2) five or more symptoms, including at least three GI symptoms.
Of the 349 persons associated with the facility who were in the population potentially at risk for infection, 315 (90%) persons were interviewed to ascertain exposure (e.g., event attendance) and illness status; 215 (68%) of the 315 interviewed had attended at least one event. Of the 215 persons, 96 (45%) had illness that was consistent with one of the case definitions; 40 cases were laboratory confirmed, and 56 were probable. All of the cases were associated with special events (i.e., none were attributable to other meals at the facility, which were prepared by the same staff and in the same kitchen), and each of the five events was associated with laboratoryconfirmed cases. Therefore, the investigation focused on identifying an item served at all five events, but not at other meals.
Only pasta salad met these criteria. In addition, pasta salad was the only food item statistically significantly associated with illness in retrospective cohort studies, which were conducted among persons who attended the two most recent events (events D and E) ( Table) ; data for 77 attendees were included in analyses. The summary relative risk for these two events (i.e., for the association between pasta salad and illness) was 32 (95% confidence interval: 5-219; p<0.001). Specifically, 90% (38 of 42) of the persons who ate the salad had cases of cyclosporiasis, compared with 3% (one of 35) of the persons who did not eat the salad. The median incubation periods for illness associated with events D and E were 8 days (range: 1-13 days) and 7 days (range: 1-10 days), respectively.
The pasta salad included multiple types of raw produce, none of which were implicated in investigations of previous outbreaks of cyclosporiasis (1) . Of the produce used in the salad (Table) , only snow peas met all of the following criteria: 1) were included in all three batches of the salad served at the five events, 2) were from the same "lot" (i.e., from one container, purchased on 1 day, and from one supplier), and 3) were not served at other meals except the five events. Event A on May 31 (Table) was the first occasion in 2004 at which pasta salad or snow peas were served by the facility.
All of the snow peas used by the facility came from the same 4.5-kg container, which was purchased on May 21 and refrigerated thereafter. On June 22, after the last (third) batch of salad was prepared (Table) , the residual snow peas were discarded; none were available for testing for Cyclospora oocysts or DNA when the investigation was initiated. In an investigation conducted by FDA, the snow peas were traced to an exporter in Guatemala.
The snow peas were handled only on days when batches of salad were prepared (Table) . For each batch, a handful of peas (approximately 1 kg) was removed from the container, washed in municipal water, and added to the salad. None of the food handlers who prepared or served the salad had symptoms consistent with cyclosporiasis before the onset of the outbreak or on the days the first two batches were prepared or served (Table) . One person who helped prepare the third batch had * Raw produce in the pasta salad, which varied among the batches, included snow peas, Vidalia onions, red peppers, tomatoes, broccoli, celery, green peppers, and carrots. However, Vidalia onions and red peppers were included in only one and two batches, respectively; different types of tomatoes were used in different batches; different "lots" of broccoli and celery, from different suppliers, were used in the various batches; and green peppers and carrots were also served raw at other meals, besides the five events.
Editorial Note: The findings of this investigation indicate that raw Guatemalan snow peas were linked to this outbreak of cyclosporiasis in Pennsylvania. No evidence of ongoing transmission has been obtained, despite heightened surveillance for cases of cyclosporiasis. This is the first investigation in which snow peas have been implicated as the vehicle of an outbreak of cyclosporiasis. Several other types of fresh produce (e.g., raspberries, basil, and mesclun lettuce), from various countries, have previously been implicated as vehicles of U.S. cyclosporiasis outbreaks (1). FDA and CDC are working with Guatemalan officials to determine the sources of the snow peas (e.g., farms or cooperatives) and possible modes of contamination. The modes of contamination of implicated vehicles have not been definitively determined for any previous foodborne outbreak of cyclosporiasis (1); better understanding of the biology and epidemiology of the parasite is needed. For imported vehicles of infection, international collaboration is critical to the success of investigations and to the identification of appropriate prevention and control measures. Produce should be thoroughly washed before it is eaten. This practice might decrease but not eliminate the risk for transmission of Cyclospora (1,3) .
Health-care providers should consider the diagnosis of Cyclospora infection in persons with prolonged or remittingrelapsing diarrheal illness and specifically request testing of stool specimens for this parasite (1); such testing is not routinely conducted by most laboratories. Trimethoprim/ sulfamethoxazole (TMP/SMX) has been shown in a placebocontrolled trial to be effective treatment for Cyclospora infection (4). Adults should receive TMP 160 mg plus SMX 800 mg (one double-strength tablet) orally, twice a day for 7 days. Some patients might benefit from longer courses of therapy. Alternative treatments for persons allergic to sulfa drugs have not yet been identified (1) .
Newly identified clusters of cases of cyclosporiasis should be investigated to identify the vehicles of infection and their sources and modes of contamination. In early August 2004, discussion with the Food and Drug Administration (FDA) and influenza vaccine manufacturers indicated that production of vaccine for the 2004-05 influenza season was proceeding satisfactorily. However, on August 26, Chiron Corporation announced that, in conducting final internal release procedures for its inactivated influenza vaccine, Fluvirin ® , the company's quality-assurance systems had identified a small number of lots that did not meet product sterility specifications; these lots will not be distributed. In recent discussions with CDC, the company stated that laboratory testing determined the problem was localized. After the company completes its quality-assurance testing, all remaining lots that have met sterility specifications will be available for distribution. Chiron expects to distribute 46-48 million doses during this influenza season, with 42-44 million doses distributed in October and the remaining doses distributed in early November. Total influenza-vaccine production from all manufacturers who will supply the U.S. market during the 2004-05 influenza season is estimated at 100 million doses, which is approximately 13 million more doses than was produced for the 2003-04 influenza season.
CDC is recommending that influenza vaccination proceed for all recommended persons as soon as vaccine is available, recognizing that availability might be limited in early October. Some delay might occur for customers receiving influenzavaccine doses purchased from Chiron, which might result in a need to reschedule planned clinics and other vaccination campaigns. The optimal time to vaccinate against influenza is October and November, and the Advisory Committee on Immunization Practices (ACIP) recommends that persons planning substantial organized vaccination campaigns consider scheduling those events after mid-October because availability of vaccine in any one location cannot be ensured CDC also will purchase 4.5 million doses of inactivated influenza vaccine, which will be held in a stockpile to ensure sufficient supply in the event of increased demand like that experienced last winter. CDC has legislative authority through the Vaccines for Children program to purchase influenza vaccine for a national stockpile program for children aged <18 years. Additional information about influenza and influenza vaccination is available from CDC at http://www.cdc.gov.
Erratum: Vol. 53, No. 34
In the report, "Suspension of Rotavirus Vaccine After Reports of Intussusception -United States, 1999," first paragraph, second sentence, the date for when rhesus-human rotavirus reassortant-tetravalent vaccine was licensed was incorrect. The date should be August 31, 1998. 
